SARS-CoV-2 spike RBD-specific IgA and IgG antibodies in breast milk after vaccination with the protein subunit vaccine Abdala

[1]  D. Oceandy,et al.  Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2 , 2022, Vaccine.

[2]  S. Zolla-Pazner,et al.  The IgA in milk induced by SARS-CoV-2 infection is comprised of mainly secretory antibody that is neutralizing and highly durable over time , 2022, PloS one.

[3]  P. Pannaraj,et al.  Human Milk SARS-CoV-2 Antibodies up to 6 Months After Vaccination. , 2022, Pediatrics.

[4]  G. Ricci,et al.  IgG and IgA Antibodies Post SARS-CoV-2 Vaccine in the Breast Milk and Sera of Breastfeeding Women , 2022, Vaccines.

[5]  Meharvan Singh,et al.  An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations , 2022, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[6]  C. D. de Groot,et al.  Comparison of SARS-CoV-2-Specific Antibodies in Human Milk after mRNA-Based COVID-19 Vaccination and Infection , 2021, Vaccines.

[7]  F. Hernández-Bernal,et al.  Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study) , 2021, eClinicalMedicine.

[8]  Anna Moratto,et al.  Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2 , 2021, Clinica Chimica Acta.

[9]  K. Järvinen,et al.  Association of Human Milk Antibody Induction, Persistence, and Neutralizing Capacity With SARS-CoV-2 Infection vs mRNA Vaccination. , 2021, JAMA pediatrics.

[10]  N. Ahituv,et al.  COVID-19 mRNA Vaccination in Lactation: Assessment of Adverse Events and Vaccine Related Antibodies in Mother-Infant Dyads , 2021, Frontiers in Immunology.

[11]  N. Ahituv,et al.  COVID-19 mRNA Vaccination in Lactation: Assessment of adverse events and vaccine related antibodies in mother-infant dyads , 2021, medRxiv.

[12]  A. Edlow,et al.  COVID-19 Vaccination in Pregnancy and Lactation: Current Research and Gaps in Understanding , 2021, Frontiers in Cellular and Infection Microbiology.

[13]  J. Bukh,et al.  Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19 , 2021, EBioMedicine.

[14]  Beatriz Reyes Millán,et al.  SARS-CoV-2 Antibodies in Breast Milk After Vaccination , 2021, Pediatrics.

[15]  Xilong Deng,et al.  Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery , 2021, Nature Communications.

[16]  B. Fox,et al.  SARS-CoV-2 Antibodies Detected in Mother’s Milk Post-Vaccination , 2021, Journal of human lactation : official journal of International Lactation Consultant Association.

[17]  G. Ogg,et al.  Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222 , 2021, medRxiv.

[18]  M. Krajewska,et al.  Immune Response to Vaccination against COVID-19 in Breastfeeding Health Workers , 2021, Vaccines.

[19]  G. Alter,et al.  Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. , 2021, JAMA.

[20]  D. Casadevall,et al.  Quantification of Specific Antibodies Against SARS-CoV-2 in Breast Milk of Lactating Women Vaccinated With an mRNA Vaccine , 2021, medRxiv.

[21]  M. Good,et al.  Anti–severe acute respiratory syndrome coronavirus 2 antibodies induced in breast milk after Pfizer-BioNTech/BNT162b2 vaccination , 2021, American Journal of Obstetrics and Gynecology.

[22]  G. Alter,et al.  Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study , 2021, American Journal of Obstetrics and Gynecology.

[23]  G. Alter,et al.  The multifaceted roles of breast milk antibodies , 2021, Cell.

[24]  Z. Cinza,et al.  Full validation of an ELISA for quantification of antibodies against Haemophilus influenzaetype b capsular polysaccharide , 2021, Journal of Applied Biotechnology & Bioengineering.

[25]  Sang-Hwan Seo,et al.  Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages , 2021, Immune network.

[26]  S. Yerly,et al.  Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study , 2021, Clinical Microbiology and Infection.

[27]  M. Chen,et al.  A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction , 2020, Nature Biotechnology.

[28]  O. Schwartz,et al.  IgA dominates the early neutralizing antibody response to SARS-CoV-2 , 2020, Science Translational Medicine.

[29]  R. Huston,et al.  Antenatal Influenza A-Specific IgA, IgM, and IgG Antibodies in Mother’s Own Breast Milk and Donor Breast Milk, and Gastric Contents and Stools from Preterm Infants , 2019, Nutrients.

[30]  Patrick Bennett,et al.  Parallelism experiments to evaluate matrix effects, selectivity and sensitivity in ligand-binding assay method development: pros and cons. , 2017, Bioanalysis.

[31]  Katherine E. Smith.  Vaccines and Chronic Disease , 2017, Delaware journal of public health.

[32]  R. Moskowitz.  Vaccines and chronic disease , 2005 .